Seminars in Hematology
Volume 40, Issue 2 , Pages 107-115 , April 2003

Molecular biology of Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus

References 

  1. Ballestas ME, Chatis PA, Kaye KM. Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science. 1999;284:641–644
  2. Bertin J, Armstrong RC, Ottilie S, et al.  Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis. Proc Natl Acad Sci USA. 1997;94:1172–1176
  3. Cahir-McFarland ED, Davidson DM, Schauer SL, et al.  NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc Natl Acad Sci USA. 2000;97:6055–6060
  4. Caldwell RG, Wilson JB, Anderson SJ, et al.  Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity. 1998;9:405–411
  5. Cho Y, Ramer J, Rivailler P, et al.  An Epstein-Barr-related herpesvirus from marmoset lymphomas. Proc Natl Acad Sci USA. 2001;98:1224–1229
  6. Clarke PA, Sharp NA, Clemens MJ. Translational control by the Epstein-Barr virus small RNA EBER-1. Reversal of the double-stranded RNA-induced inhibition of protein synthesis in reticulocyte lysates. Eur J Biochem. 1990;193:635–641
  7. Cohen J, Wang F, Kieff E. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci USA. 1989;86:9558–9562
  8. Cohen JI, Kieff E. An Epstein-Barr virus nuclear protein 2 domain essential for transformation is a direct transcriptional activator. J Virol. 1991;65:5880–5885
  9. Cotter MA, Robertson ES. The latency-associated nuclear antigen tethers the Kaposi's sarcoma-associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells. Virology. 1999;264:254–264
  10. Cotter MA, Subramanian C, Robertson ES. The Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen binds to specific sequences at the left end of the viral genome through its carboxy-terminus. Virology. 2001;291:241–259
  11. Devergne O, Hatzivassiliou E, Izumi KM, et al.  Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: Role in NF-kappaB activation. Mol Cell Biol. 1996;16:7098–7108
  12. Djerbi M, Screpanti V, Catrina AI, et al.  The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med. 1999;190:1025–1032
  13. Eliopoulos AG, Blake SM, Floettmann JE, et al.  Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2. J Virol. 1999;73:1023–1035
  14. Eliopoulos AG, Stack M, Dawson CW, et al.  Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kappaB pathway involving TNF receptor-associated factors. Oncogene. 1997;14:2899–2916
  15. Ellis M, Chew YP, Fallis L, et al.  Degradation of p27(Kip) cdk inhibitor triggered by Kaposi's sarcoma virus cyclin-cdk6 complex. EMBO J. 1999;18:644–653
  16. Epstein M, Achong B, Barr YM. Virus particles in cultured lympoblasts from Burkitt's lymphoma. Lancet. 1964;1:702–703
  17. Flore O, Rafii S, Ely S, et al.  Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus. Nature. 1998;394:588–592
  18. Friborg J, Kong W, Hottiger MO, et al.  p53 inhibition by the LANA protein of KSHV protects against cell death. Nature. 1999;402:889–894
  19. Frisan T, Zhang QJ, Levitskaya J, et al.  Defective presentation of MHC class I-restricted cytotoxic T-cell epitopes in Burkitt's lymphoma cells. Int J Cancer. 1996;68:251–258
  20. Gilligan K, Rajadurai P, Resnick L, et al.  Epstein-Barr virus small nuclear RNAs are not expressed in permissively infected cells in AIDS-associated leukoplakia. Proc Natl Acad Sci USA. 1990;87:8790–8794
  21. Goodbourn S. Signal transduction. Notch takes a short cut. Nature. 1995;377:288–289
  22. Grossman SR, Johannsen E, Tong X, et al.  The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein. Proc Natl Acad Sci USA. 1994;91:7568–7572
  23. Hammerschmidt W, Sugden B. Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature. 1987;340:393–397
  24. Han I, Harada S, Weaver D, et al.  EBNA-LP associates with cellular proteins including DNA-PK and HA95. J Virol. 2001;75:2475–2481
  25. Harada S, Kieff E. Epstein-Barr virus nuclear protein LP stimulates EBNA-2 acidic domain-mediated transcriptional activation. J Virol. 1997;71:6611–6618
  26. Henderson S, Rowe M, Gregory C, et al.  Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell. 1991;65:1107–1115
  27. Henkel T, Ling PD, Hayward SD, et al.  Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein J kappa. Science. 1994;265:92–95
  28. Howe JG, Steitz JA. Localization of Epstein-Barr virus-encoded small RNAs by in situ hybridization. Proc Natl Acad Sci USA. 1986;83:9006–9010
  29. Izumi KM, Cahir McFarland ED, et al. , The :  Epstein-Barr virus oncoprotein latent membrane protein 1 engages the tumor necrosis factor receptor-associated proteins TRADD and receptor-interacting protein (RIP) but does not induce apoptosis or require RIP for NF-kappaB activation. Mol Cell Biol. 1999;19:5759–5767
  30. Jenner RG, Boshoff C. The molecular pathology of Kaposi's sarcoma-associated herpesvirus. Biochim Biophys Acta. 2002;1602:1–22
  31. Kaye KM, Devergne O, Harada JN, et al.  Tumor necrosis factor receptor associated factor 2 is a mediator of NF- kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. Proc Natl Acad Sci USA. 1996;93:11085–11090
  32. Kaye KM, Izumi KM, Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci USA. 1993;90:9150–9154
  33. Kieff E. Epstein-Barr virus and its replication. In:  Fields BN,  Knipe DM,  Howley PM editor. Virology. Philadelphia, PA: Lippincott-Raven; 1996;p. 2343–2396
  34. Komano J, Sugiura M, Takada K. Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata. J Virol. 1998;72:9150–9156
  35. Krithivas A, Young DB, Liao G, et al.  Human herpesvirus 8 LANA interacts with proteins of the mSin3 corepressor complex and negatively regulates Epstein-Barr virus gene expression in dually infected PEL cells. J Virol. 2000;74:9637–9645
  36. Kulwichit W, Edwards RH, Davenport EM, et al.  Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci USA. 1998;95:11963–11968
  37. Laherty CD, Hu HM, Opipari AW, et al.  The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. J Biol Chem. 1992;267:24157–24160
  38. Lerner MR, Andrews NC, Miller G, et al.  Two small RNAs encoded by Epstein-Barr virus and complexed with protein are precipitated by antibodies from patients with systemic lupus erythematosus. Proc Natl Acad Sci USA. 1981;78:805–809
  39. Levitskaya J, Coram M, Levitsky V, et al.  Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature. 1995;375:685–688
  40. Longnecker R, Miller CL, Miao XQ, et al.  The only domain which distinguishes Epstein-Barr virus latent membrane protein 2A (LMP2A) from LMP2B is dispensable for lymphocyte infection and growth transformation in vitro; LMP2A is therefore nonessential. J Virol. 1992;66:6461–6469
  41. Longnecker R, Miller CL, Miao XQ, et al.  The last seven transmembrane and carboxy-terminal cytoplasmic domains of Epstein-Barr virus latent membrane protein 2 (LMP2) are dispensable for lymphocyte infection and growth transformation in vitro. J Virol. 1993;67:2006–2013
  42. Mann DJ, Child ES, Swanton C, et al.  Modulation of p27(Kip1) levels by the cyclin encoded by Kaposi's sarcoma-associated herpesvirus. EMBO J. 1999;18:654–663
  43. Mannick JB, Cohen JI, Birkenbach M, et al.  The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation. J Virol. 1991;65:6826–6837
  44. Marshall D, Sample C. Epstein-Barr virus nuclear antigen 3C is a transcriptional regulator. J Virol. 1995;69:3624–3630
  45. Miller CL, Burkhardt AL, Lee JH, et al.  Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein- tyrosine kinases. Immunity. 1995;2:155–166
  46. Miller CL, Longnecker R, Kieff E. Epstein-Barr virus latent membrane protein 2A blocks calcium mobilization in B lymphocytes. J Virol. 1993;67:3087–3094
  47. Moore KW, Vieira P, Fiorentino DF, et al.  Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science. 1990;248:1230–1234
  48. Moore PS, Chang Y. Molecular virology of Kaposi's sarcoma-associated herpesvirus. Philos Trans R Soc Lond B Biol Sci. 2001;356:499–516
  49. Mosialos G, Birkenbach M, Yalamanchili R, et al.  The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell. 1995;80:389–399
  50. Qu L, Rowe DT. Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes. J Virol. 1992;66:3715–3724
  51. Rabson M, Gradoville L, Heston L, et al.  Non-immortalizing P3J-HR1 Epstein Barr virus: A deletion mutant of its transforming parent, Jijoye. J Virol. 1982;48:834–844
  52. Radkov SA, Kellam P, Boshoff C. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med. 2000;6:1121–1127
  53. Rickinson AB, Kieff E. Epstein-Barr virus. In:  Fields BN,  Knipe DM,  Howley PM editor. Virology. Philadelphia, PA: Lippincott-Raven; 1996;p. 2397–2436
  54. Robertson ES, Lin J, Kieff E. The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJ(kappa). J Virol. 1996;70:3068–3074
  55. Rose TM, Strand KB, Schultz ER, et al.  Identification of two homologs of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in retroperitoneal fibromatosis of different macaque species. J Virol. 1997;71:4138–4144
  56. Ruf IK, Rhyne PW, Yang C, et al.  Epstein-Barr virus small RNAs potentiate tumorigenicity of Burkitt lymphoma cells independently of an effect on apoptosis. J Virol. 2000;74:10223–10228
  57. Ruf IK, Rhyne PW, Yang H, et al.  Epstein-Barr Virus Regulates c-MYC, Apoptosis, and Tumorigenicity in Burkitt Lymphoma. Mol. Cell. Biol. 1999;19:1651–1660
  58. Searles RP, Bergquam EP, Axthelm MK, et al.  Sequence and genomic analysis of a Rhesus macaque rhadinovirus with similarity to Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8. J Virol. 1999;73:3040–3053
  59. Shimizu N, Tanabe-Tochikura A, Kuroiwa Y, et al.  Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: Malignant phenotypes of BL cells are dependent on EBV. J Virol. 1994;68:6069–6073
  60. Swaminathan S, Hesselton R, Sullivan J, et al.  Epstein-Barr virus recombinants with specifically mutated BCRF1 genes. J Virol. 1993;67:7406–7413
  61. Swaminathan S, Tomkinson B, Kieff E. Recombinant Epstein-Barr virus with small RNA (EBER) genes deleted transforms lymphocytes and replicates in vitro. Proc Natl Acad Sci U S A. 1991;88:1546–1550
  62. Swanton C, Mann DJ, Fleckenstein B, et al.  Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature. 1997;390:184–187
  63. Takada K. Role of Epstein-Barr virus in Burkitt's lymphoma. Curr Top Microbiol Immunol. 2001;258:141–151
  64. Takeshita H, Yoshizaki T, Miller WE, et al.  Matrix metalloproteinase 9 expression is induced by Epstein-Barr virus latent membrane protein 1 C-terminal activation regions 1 and 2. J Virol. 1999;73:5548–5555
  65. Thome M, Schneider P, Hofmann K, et al.  Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature. 1997;386:517–521
  66. Tierney RJ, Steven N, Young LS, et al.  Epstein-Barr virus latency in blood mononuclear cells: Analysis of viral gene transcription during primary infection and in the carrier state. J Virol. 1994;68:7374–7385
  67. Toczyski DP, Steitz JA. EAP, a highly conserved cellular protein associated with Epstein-Barr virus small RNAs (EBERs). EMBO J. 1991;10:459–466
  68. Tomkinson B, Robertson E, Kieff E. Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J Virol. 1993;67:2014–2025
  69. Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell. 1985;43:831–840
  70. Wang D, Liebowitz D, Wang F, et al.  Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: Deletion of the amino terminus abolishes activity. J Virol. 1988;62:4173–4184
  71. Wang F, Gregory CD, Rowe M, et al.  Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. Proc Natl Acad Sci USA. 1987;84:3452–3456
  72. Wang F, Tsang SF, Kurilla MG, et al.  Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J Virol. 1990;64:3407–3416
  73. Wilson JB, Bell JL, Levine AJ. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J. 1996;15:3117–3126
  74. Yalamanchili R, Tong X, Grossman S, et al.  Genetic and biochemical evidence that EBNA 2 interaction with a 63-kDa cellular GTG-binding protein is essential for B lymphocyte growth transformation by EBV. Virology. 1994;204:634–641
  75. Yates JL, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature. 1985;313:812–815

☆ 0037-1963/03/4002-0001$30.00/0

PII: S0037-1963(03)70002-X

Seminars in Hematology
Volume 40, Issue 2 , Pages 107-115 , April 2003

Article Tools

* Image Usage & Resolution